First Horizon Advisors’s Axsome Therapeutics AXSM Stock Holding History

First Horizon Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11	Closed	-$1.28K	–	2328
2025 Q1	$1.28K	Sell	11 -5	-31%	-$570	﹤0.01%	2080
2024 Q4	$1.35K	Hold	16	–	–	﹤0.01%	2060
2024 Q3	$1.44K	Hold	16	–	–	﹤0.01%	2077
2024 Q2	$1.29K	Hold	16	–	–	﹤0.01%	2075
2024 Q1	$1.28K	Hold	16	–	–	﹤0.01%	2115
2023 Q4	$1.27K	Hold	16	–	–	﹤0.01%	2152
2023 Q3	$1.12K	Sell	16 -21	-57%	-$1.57K	﹤0.01%	2162
2023 Q2	$2.66K	Hold	37	–	–	﹤0.01%	1992
2023 Q1	$2.28K	Hold	37	–	–	﹤0.01%	2061
2022 Q4	$2.85K	Hold	37	–	–	﹤0.01%	1956
2022 Q3	$1K	Hold	37	–	–	﹤0.01%	2085
2022 Q2	$1K	Buy	37 +13	+54%	+$411	﹤0.01%	2181
2022 Q1	$1K	Sell	24 -125	-84%	-$3.88K	﹤0.01%	1519
2021 Q4	$5K	Hold	149	–	–	﹤0.01%	1735
2021 Q3	$4K	Buy	149 +112	+303%	+$4.37K	﹤0.01%	1780
2021 Q2	$2K	Buy	37 +16	+76%	+$960	﹤0.01%	1733
2021 Q1	$1K	Buy	+21	New	+$1.48K	﹤0.01%	1742

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

First Horizon Advisors's AXSM Position: Q2 2025 in Review

First Horizon Advisors sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 11 shares — an estimated $1.28K sold.

First Horizon Advisors first reported a position in AXSM in Q1 2021 and held it in 17 quarters. The position peaked at $5K in Q4 2021. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

First Horizon Advisors reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
First Horizon Advisors sold 11 Axsome Therapeutics shares in Q2 2025, an estimated $1.28K.
First Horizon Advisors first reported a position in Axsome Therapeutics in Q1 2021 and held it in 17 quarters.
First Horizon Advisors's Axsome Therapeutics position peaked at $5K in Q4 2021.
348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.